{"data":{"id":"10.6084/m9.figshare.3863616","type":"dois","attributes":{"doi":"10.6084/m9.figshare.3863616","prefix":"10.6084","suffix":"m9.figshare.3863616","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Prokaeva, Tatiana","nameType":"Personal","givenName":"Tatiana","familyName":"Prokaeva","affiliation":[],"nameIdentifiers":[]},{"name":"Spencer, Brian","nameType":"Personal","givenName":"Brian","familyName":"Spencer","affiliation":[],"nameIdentifiers":[]},{"name":"Fangui Sun","affiliation":[],"nameIdentifiers":[]},{"name":"O’Hara, Richard M.","nameType":"Personal","givenName":"Richard M.","familyName":"O’Hara","affiliation":[],"nameIdentifiers":[]},{"name":"Seldin, David C.","nameType":"Personal","givenName":"David C.","familyName":"Seldin","affiliation":[],"nameIdentifiers":[]},{"name":"Lawreen H. Connors","affiliation":[],"nameIdentifiers":[]},{"name":"Sanchorawala, Vaishali","nameType":"Personal","givenName":"Vaishali","familyName":"Sanchorawala","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio"}],"publisher":"Taylor \u0026 Francis","container":{},"publicationYear":2016,"subjects":[{"subject":"29999 Physical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"FOS: Physical sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Physical sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Medicine"},{"subject":"Cell Biology"},{"subject":"Physiology"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Biological sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Biotechnology"},{"subject":"Immunology"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Clinical medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Cancer"},{"subject":"Hematology"},{"subject":"60506 Virology","subjectScheme":"FOR"}],"contributors":[],"dates":[{"date":"2016-09-28","dateType":"Created"},{"date":"2016-12-05","dateType":"Updated"},{"date":"2016","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[{"relationType":"IsSupplementTo","relatedIdentifier":"10.1080/13506129.2016.1219715","relatedIdentifierType":"DOI"}],"relatedItems":[],"sizes":["1780760 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"\u003ci\u003eBackground\u003c/i\u003e: Serum and urine immunofixation electrophoreses (SIFE/UIFE) are used for clonal detection in plasma cell dyscrasias, while serum free light chain (sFLC) testing provides quantitation of clonal disease. Up to 20% of patients with light chain (AL) amyloidosis may present with normal FLC ratio (FLCr). \u003ci\u003eMethods\u003c/i\u003e: We assessed the diagnostic, quantitative and prognostic potential of serum heavy light chain ratio (HLCr) in 199 untreated patients at initial evaluation. \u003ci\u003eResults\u003c/i\u003e: An abnormal HLCr was found in 37.2%, abnormal FLCr in 81.9% and positivity by SIFE/UIFE in 94% of patients. HLCr together with SIFE/UIFE identified clonality in 94% patients; the combination with FLCr yielded 100% sensitivity. An HLCr abnormality was significantly over-represented in normal compared to abnormal FLCr group (63.9% versus 31.3%). HLCr did not predict overall survival (OS) (log rank, \u003ci\u003ep \u003c/i\u003e=\u003ci\u003e \u003c/i\u003e0.09), while an abnormal FLCr was associated with decreased OS (log rank, \u003ci\u003ep \u003c/i\u003e=\u003ci\u003e \u003c/i\u003e0.03). The combined use of both ratios trended toward increased OS in the abnormal HLCr/normal FLCr group (log rank, \u003ci\u003ep \u003c/i\u003e=\u003ci\u003e \u003c/i\u003e0.11; Wilcoxon, \u003ci\u003ep \u003c/i\u003e=\u003ci\u003e \u003c/i\u003e0.04). On multivariate analysis, HLCr was not predictive of OS, whereas an abnormal FLCr was associated with shorter OS (HR = 1.7, \u003ci\u003ep \u003c/i\u003e=\u003ci\u003e \u003c/i\u003e0.04). \u003ci\u003eConclusions\u003c/i\u003e: The HLC assay has potential as a supplemental test to quantify monoclonal protein in patients with normal FLCr results.","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"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","url":"https://tandf.figshare.com/articles/dataset/Immunoglobulin_heavy_light_chain_test_quantifies_clonal_disease_in_patients_with_AL_amyloidosis_and_normal_serum_free_light_chain_ratio/3863616","contentUrl":null,"metadataVersion":2,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":1,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2016-09-28T08:58:12.000Z","registered":"2016-09-28T08:58:13.000Z","published":"2016","updated":"2020-09-03T14:29:08.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.3863616","type":"media"}},"references":{"data":[{"id":"10.1080/13506129.2016.1219715","type":"dois"}]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}